<root xmlns:xlink="http://www.w3.org/1999/xlink">
    <article>
        <journal-meta>
            <journal-id journal-id-type="publisher-id">eLife</journal-id>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">00666</article-id>
            <article-id pub-id-type="doi">10.7554/eLife.00666</article-id>
            <title-group>
                <article-title>The eLife research article</article-title>
            </title-group>
        </article-meta>
        <sub-article article-type="editor-report" id="sa0">
            <front-stub>
                <article-id pub-id-type="doi">10.7554/eLife.00666.sa0</article-id>
                <title-group>
                    <article-title>Editor's evaluation</article-title>
                </title-group>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>Ma</surname>
                            <given-names>Yuting</given-names>
                        </name>
                        <role specific-use="editor">Reviewing Editor</role>
                        <aff>
                            <institution>Suzhou Institute of Systems Medicine</institution>
                            <country>China</country>
                        </aff>
                    </contrib>
                </contrib-group>
            <related-object link-type="hasRelatedMaterial" xlink:href="https://sciety.org/articles/activity/10.1101/2020.11.21.391326"/>
            </front-stub>
            <body>
                <p>Collagen is a major component of extracellular matrix. The authors have identified a high-affinity inhibitory collagen receptor LAIR-1 and a soluble decoy receptor LAIR-2 (with even higher binding affinity to collagen), which can be therapeutically targeted to block tumor progression. Dr Meyaard and colleagues have also generated a dimeric LAIR-2 human IgG1 Fc fusion protein NC410 for therapeutic use. With humanized mouse models engrafted with functional human immune systems (PBMC), they have explored the anti-cancer efficacy of NC410 and revealed its impact on modulating immune responses. Furthermore, they extended this study to identify biomarkers of predictive value for NC410-based anti-cancer therapy.</p>
            </body>
        </sub-article>
    </article>
</root>